NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis $1.32 -0.03 (-2.22%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About DURECT Stock (NASDAQ:DRRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DURECT alerts:Sign Up Key Stats Today's Range$1.27▼$1.3750-Day Range$1.22▼$1.6252-Week Range$0.47▼$3.14Volume41,594 shsAverage Volume137,851 shsMarket Capitalization$40.97 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingHold Company OverviewDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More… 24/7 Automated Profits in Crypto (Ad)What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.>> Secure Your Spot On The Groundbreaking Workshop Here DURECT Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks68th Percentile Overall ScoreDRRX MarketRank™: DURECT scored higher than 68% of companies evaluated by MarketBeat, and ranked 372nd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingDURECT has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDURECT has only been the subject of 1 research reports in the past 90 days.Read more about DURECT's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for DURECT are expected to decrease in the coming year, from ($0.78) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about DURECT's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.30% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in DURECT has recently increased by 1.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.19 Percentage of Shares Shorted3.30% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in DURECT has recently increased by 1.93%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.93 News SentimentDURECT has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DURECT this week, compared to 1 article on an average week.Search Interest2 people have searched for DRRX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions.Read more about DURECT's insider trading history. Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Stock News HeadlinesStockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)October 29 at 2:09 AM | americanbankingnews.comDURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024October 17, 2024 | prnewswire.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.October 31, 2024 | Crypto Swap Profits (Ad)Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ...October 10, 2024 | finance.yahoo.comDURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated HepatitisSeptember 25, 2024 | prnewswire.comDURECT Corporation to Present at the H.C. Wainwright Global Investment ConferenceSeptember 4, 2024 | prnewswire.comDRRX Apr 2025 2.000 putAugust 29, 2024 | ca.finance.yahoo.comDRRX Apr 2025 2.000 callAugust 29, 2024 | ca.finance.yahoo.comSee More Headlines DRRX Stock Analysis - Frequently Asked Questions How have DRRX shares performed this year? DURECT's stock was trading at $0.59 at the start of the year. Since then, DRRX stock has increased by 116.9% and is now trading at $1.28. View the best growth stocks for 2024 here. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) posted its quarterly earnings data on Tuesday, August, 13th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.05. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to the consensus estimate of $2.49 million. DURECT had a negative trailing twelve-month return on equity of 261.43% and a negative net margin of 187.80%. When did DURECT's stock split? DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), General Electric (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE). Company Calendar Last Earnings8/13/2024Today10/31/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$37.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,455.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,620,000.00 Net Margins-187.80% Pretax Margin-187.84% Return on Equity-261.43% Return on Assets-66.98% Debt Debt-to-Equity RatioN/A Current Ratio0.91 Quick Ratio0.80 Sales & Book Value Annual Sales$8.41 million Price / Sales4.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book2.70Miscellaneous Outstanding Shares31,039,000Free Float30,046,000Market Cap$41.90 million OptionableOptionable Beta1.13 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:DRRX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.